Survival
Inhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma
Oncogenesis 2025 August 11 [Link] Yantang Lin, Christelle Dubey, Tereza Losmanova, Samuel Oevgü Yasmin, Jean-Louis Reymond, Ren-Wang Peng, Haibin Deng, Patrick Dorn, Thomas Michael Marti Abstract Pleural mesothelioma (PM) is an aggressive, asbestos-linked cancer with limited treatment options and a poor prognosis. Lactate dehydrogenase B (LDHB) converts lactate to pyruvate, and its silencing reduces mitochondrial…
Read MoreFirst-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study
Lung Cancer 2025 August 5 [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Daniel C Christoph 4, Frank Griesinger, Martin Reck, Petra Hoffknecht, Jonas Kuo, Nikolaj Frost, Christian Grohé, Martin Faehling, Jingting Luan, Julia Roeper, Paolo Chesi, Miriam Blasi, Martin Kimmich, Till Olchers, Helge Bischoff, Laura V Klotz, Inn Chung, Petros Christopoulos, Michael Thomas Abstract…
Read MoreTowards a new approach in pleural mesothelioma: Perioperative immunotherapy and its implications
Critical Reviews in Oncology/Hematology 2025 July 23 [Link] Paolo Ambrosini, Alessia Stanzi, Giuseppe Lo Russo, Piergiorgio Solli, Mario Occhipinti Abstract Pleural mesothelioma is a rare malignancy that has historically had a poor prognosis, even with systemic chemotherapy. Although immune checkpoint inhibitors have improved survival rates for patients with advanced, unresectable disease, their role in perioperative…
Read MoreA giant peritoneal mesothelioma extending to the pelvic floor: A case report and review of the literature
Journal of Cancer Research and Therapeutics 2025 April 1 [Link] Mathew Thomas, Harikrishnan Nandakumar, Parth Sampat, Stephen Graziano Abstract Malignant peritoneal mesothelioma (MPM) is a rare malignancy originating from the peritoneal serosa and is the second most common site of mesothelioma after the pleura. Localized disease presents as a focal circumscribed mass, whereas diffuse disease…
Read MoreProlonged Survival in Mesothelioma Patients Without Surgical Resection: A National Cancer Database Analysis
The Annals of Thoracic Surgery 2025 June 28 [Link] Peter L Zhan, Maureen E Canavan, Justin M Bader, Daniel J Boffa, Benjamin J Resio, Gavitt A Woodard Abstract Background: The Mesothelioma and Radical Surgery 2 (MARS 2) trial demonstrated no survival benefit from cytoreductive surgical resection over chemotherapy alone in resectable pleural mesothelioma. Using the…
Read MoreClinical and Pathologic Phenotyping of mesotheliomas developing in carriers of Germline BAP1 Mutations
Journal of Thoracic Oncology 2025 June 27 [Link] Michele Carbone, Michael Minaai, Muaiad Kittaneh, Thomas Krausz, Markku M Miettinen, Qiang Pan Hammarström, Lennart Hammarström, Hassan Abolhassani, Ian Pagano, Ronghui Xu, Flavia Novelli, Giovanni Gaudino, Sandra Pastorino, Kavita Y Sarin, Robert T Ripley, Harvey I Pass, David S Schrump , Haining Yang Abstract Introduction: Mesothelioma is…
Read MorePBK Expression Promotes the Aggressive Phenotypes of Mesothelioma
Cancer Science 2025 June 24 [Link] Kazumi Hori, Ichidai Tanaka, Tatsuhiro Sato, Mika Sato, Yuta Kodama, Hideyuki Itoigawa, Yuichi Abe, Taketo Kato, Ayumu Taguchi, Mitsuo Sato, Yoshitaka Sekido, Toyofumi Fengshi Chen-Yoshikawa, Makoto Ishii Abstract Mesothelioma is one of the most aggressive neoplasms worldwide that has a particularly poor prognosis. We have previously discovered that oxytocin…
Read MoreIdentification of a novel prognostic gene signature in pleural mesothelioma: a study based on The Cancer Genome Atlas database and experimental validation
Translational Cancer Research 2025 May 30 [Link] Xinmeng Wang, Yongqin Yang, Wenzhong Yang, Xi Yang, Jinsong Li, Yaru Lin, Zhengliang Li, Jiangyan Li, Wei Xiong Abstract Background: Early detection and prognostic prediction are crucial in improving the survival of patients with pleural mesothelioma (PM). Therefore, this study aimed to develop a gene prognostic risk model…
Read MoreCharacteristics of Long-Term Survivors With Peritoneal Mesothelioma – Insights From the National Cancer Database
The American Surgeon 2025 June 17 [Link] Himani Bhatt, Deep P Vakil, Luis Quintero, Monique Motta, Maria Vashchenko, Bettsy Rodriguez, Shenae K Samuels, Kumar Jayant, Jonathan Magloire, Christopher J Gannon, Omar H Llaguna Abstract Introduction: Peritoneal mesothelioma (PM) is a rare cancer associated with high mortality. No studies exist using the National Cancer Database (NCDB)…
Read MoreMolecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities
Diagnostics (Basel) 2025 May 24 [Link] Teodora Zahiu, Carmen Mihaela Mihu, Bianca A Bosca, Mariana Mărginean, Lavinia Patricia Mocan, Roxana-Adelina Ștefan, Rada Teodora Suflețel, Carina Mihu, Carmen Stanca Melincovici Abstract Pleural mesothelioma (PM) is a rare disease, which is going to be a global medical concern in the 21st century, because of its aggressiveness, late…
Read More
Skip to content